Tag:

Genzyme

Latest Headlines

Latest Headlines

Sanofi yanks drug batch on CMO contamination fears

Here's another ripple from the Ben Venue Laboratories splashdown. Sanofi's ($SNY) Genzyme unit has recalled a batch of its leukemia drug Fludara because of worries about its sterility. The 9,380

Sanofi CEO: Look out below, profits are falling

It wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3...

How do the 12 priciest drugs in the U.S. stack up?

Last week, Vertex Pharmaceuticals ($VRTX) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as

Is Sanofi destined to be 'small player' in MS?

Sanofi ($SNY) CEO Chris Viehbacher (photo) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme. But advances by other companies are making it

Genzyme wins key FDA approval for new plant

You can bet that Sanofi's ($SNY) top brass are celebrating this evening. The French drugmaker's Genzyme unit won the long-sought FDA approval for its new plant in Framingham, MA. That facility can

Genzyme revives Fabrazyme with EMA plant OK

Genzyme flexed some market muscle Wednesday when it announced the European Medicines Agency's approval of a new U.S. facility for production of Fabrazyme. Perhaps most immediately affected by the...

Genzyme's new plant nabs approval from EMA

Sanofi ($SNY) is looking forward to ending long-running supply problems at Genzyme. The company said Genzyme's new manufacturing plant in Framingham, MA, won approval from European regulators to

Genzyme's new plant to boost Fabrazyme supply

Genzyme says that, barring validation and regulatory hiccups, it expects to begin providing Fabry disease sufferers with Fabrazyme produced at its new Framingham, MA, plant beginning the first

Hospira enters angry-investor phase of remediation

Hospira ($HSP) shareholders claim the company didn't disclose the extent of problems at its North Carolina plant. Yet CEO Michael Ball admitted in October 2011 that the remediation job was " bigger

Ben Venue lengthens remediation timeline

Ben Venue Labs is extending the timeline for remediation at an Ohio plant—and along with it the expected availability of some critical drugs currently in short supply. The company made the